Citi Doubles Mirati Target, Says 135% Rally 'Not Nearly Enough'
September 19, 2017 at 09:08 AM EDT
Citi analyst Yigal Nochomovitz now models $300M peak revenue for sitravatinib in NSCLC with inactivating CBL mutations. The analyst keeps a Buy rating on Mirati.
